CommercialCoverageMedium impact
Noninvasive Techniques for the Evaluation and Monitoring of Patients With Chronic Liver Disease (2.04.41)
Blue Shield of California·CA · Gastroenterology, Internal Medicine, Family Medicine·Medical Policy
Effective date
Jan 1, 2026
We identified it
Nov 1, 2025
Summary
Blue Shield of California updated their policy on noninvasive liver disease evaluation, effective January 1, 2026. FibroSURE multianalyte assays and transient elastography (FibroScan) are now considered medically necessary for evaluation of chronic liver disease patients, but remain investigational for monitoring purposes.
Action Required
Before January 1, 2026: Billing team must update prior authorization protocols to reflect that FibroSURE multianalyte assays and transient elastography (FibroScan) are covered for evaluation of chronic liver disease but require prior auth for monitoring uses. Update billing system to flag monitoring claims as investigational/non-covered. Train providers on the distinction between evaluation vs. monitoring indications for these services.